AmFAR extols FDA on rapid approval of two protease inhibitors.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005582:Foundations; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use*; D009316:National Institutes of Health (U.S.); D012106:Research; D019438:Ritonavir / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D019438:Ritonavir